

References

I-136

1. National Comprehensive Cancer Network (NCCN). Brentuximab vedotin. NCCN Drugs and Biologics Compendium®. 2020.
2. Gravanis I, Tzogani K, Pignatti F, et al. The european medicines agency review of brentuximab vedotin (adcetris) for the treatment of adult patients with relapsed or refractory CD30+ hodgkin lymphoma or systemic anaplastic large cell lymphoma: summary of the scientific assessment of the committee for medicinal products for human use. *The Oncologist*. January 2016;21(1):102-109.
3. Gandolfi L, Pellegrini C, Zinzani P, et al. Long-term responders after brentuximab vedotin: single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients. *The Oncologist*. 2016;21(12):1436-1441.
4. Kuznar W. Brentuximab vedotin improves responses lasting 4 months in cutaneous T-cell lymphoma. *American Health & Drug Benefits*. 2017;10:14-16.
5. Rubio-Gonzalez B, Zain J, Garcia L, Rosen S, Querfeld C. Cutaneous gamma-delta T-cell lymphoma successfully treated with brentuximab vedotin. *JAMA Dermatology*. 2016.
6. Kim YH, Tavallae M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. *Journal of Clinical Oncology*. 2015;33(32):3750-3761.